Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | JACC: Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772963X25002777 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850131069801594880 |
|---|---|
| author | Patrick A. Kwaah, MBChB Samuel A. Mensah, MBChB Abraham Carboo, MBChB, MPH Hamza A. Rashid, MBBS Emmanuel A. Agyemang, MBChB Grace Appah, MBChB Smith K. Frimpong, MD |
| author_facet | Patrick A. Kwaah, MBChB Samuel A. Mensah, MBChB Abraham Carboo, MBChB, MPH Hamza A. Rashid, MBBS Emmanuel A. Agyemang, MBChB Grace Appah, MBChB Smith K. Frimpong, MD |
| author_sort | Patrick A. Kwaah, MBChB |
| collection | DOAJ |
| format | Article |
| id | doaj-art-cbfbd3a1b3b04c1b9eab9718595e4e24 |
| institution | OA Journals |
| issn | 2772-963X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Advances |
| spelling | doaj-art-cbfbd3a1b3b04c1b9eab9718595e4e242025-08-20T02:32:31ZengElsevierJACC: Advances2772-963X2025-07-014710185710.1016/j.jacadv.2025.101857Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEFPatrick A. Kwaah, MBChB0Samuel A. Mensah, MBChB1Abraham Carboo, MBChB, MPH2Hamza A. Rashid, MBBS3Emmanuel A. Agyemang, MBChB4Grace Appah, MBChB5Smith K. Frimpong, MD6Department of Internal Medicine, Yale School of Medicine, Waterbury, Connecticut, USA; Address for correspondence: Dr Patrick A. Kwaah, Yale School of Medicine, 64 Robbins Street, Waterbury, Connecticut 06708, USA.Department of Internal Medicine, West Virginia University, Morgantown, West Virginia, USADepartment of Internal Medicine, Yale School of Medicine, Waterbury, Connecticut, USADepartment of Internal Medicine, Yale School of Medicine, Waterbury, Connecticut, USADepartment Internal Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, USADepartment of Internal Medicine, Yale School of Medicine, Waterbury, Connecticut, USADepartment of Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, USAhttp://www.sciencedirect.com/science/article/pii/S2772963X25002777cardiovascular outcomesdulaglutideGLP-1 receptor agonistsheart failure with preserved ejection fraction (HFpEF)non-obesesemaglutide |
| spellingShingle | Patrick A. Kwaah, MBChB Samuel A. Mensah, MBChB Abraham Carboo, MBChB, MPH Hamza A. Rashid, MBBS Emmanuel A. Agyemang, MBChB Grace Appah, MBChB Smith K. Frimpong, MD Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF JACC: Advances cardiovascular outcomes dulaglutide GLP-1 receptor agonists heart failure with preserved ejection fraction (HFpEF) non-obese semaglutide |
| title | Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF |
| title_full | Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF |
| title_fullStr | Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF |
| title_full_unstemmed | Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF |
| title_short | Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF |
| title_sort | cardiovascular outcomes of semaglutide vs dulaglutide in nonobese type ii diabetes patients with hfpef |
| topic | cardiovascular outcomes dulaglutide GLP-1 receptor agonists heart failure with preserved ejection fraction (HFpEF) non-obese semaglutide |
| url | http://www.sciencedirect.com/science/article/pii/S2772963X25002777 |
| work_keys_str_mv | AT patrickakwaahmbchb cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT samuelamensahmbchb cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT abrahamcarboombchbmph cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT hamzaarashidmbbs cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT emmanuelaagyemangmbchb cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT graceappahmbchb cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef AT smithkfrimpongmd cardiovascularoutcomesofsemaglutidevsdulaglutideinnonobesetypeiidiabetespatientswithhfpef |